UEG spokesperson and researcher Michael Scharl, MD, and colleagues analyzed 1,012 patients from seven different studies to identify the presence of fecal lactoferrin, a biomarker that distinguishes between IBD and IBS.
Here are four points:
1. Researchers found patients who used fecal lactoferrin had a 0.78 sensitivity rate and a 0.94 specificity rate.
2. The positive likelihood ratio was 12.31 and the negative likelihood ratio was 0.23.
3. The diagnostic odds ratio was 52.65.
4. The researchers conclude fecal lactoferrin is an accurate method to differentiate between IBD and IBS.
More articles on GI & endoscopy:
GI physician leader to know: Dr. Michael Camilleri of Mayo Medical School
PENTAX Medical names Dr. Hudson Garrett global chief clinical officer, FDA approves Gilead Sciences’ new chronic HCV drug — 6 GI company key notes
FDA approves Gilead Sciences’ Epclusa for chronic HCV: 4 observations
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
